IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt’s lymphoma

Bellone, Michael; Zaslav, Ann-Leslie; Ahmed, Tahmeena; Lee, Htien L; Ma, Yupo; Hu, Youjun

doi:10.1186/2050-7771-2-9

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a group of cases which are introduced as “B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma” [ 24 ] has received increased attention. These are likely to share some but not all pathogenetic features of classic BL, or arise as a result of alternative primary molecular events that nonetheless deregulate the common oncogenic pathways [ 25 , 26 ]. This group appears to respond poorly to either intensive treatment or R-CHOP-like regimes [ 27 – 29 ], and the underlying mechanism remains largely unknown and the appropriate treatment still needs to be established.…”

Section: Introductionmentioning

confidence: 99%

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas

Sha¹,

Barrans²,

Care³

et al. 2015

Genome Med

View full text Add to dashboard Cite

BackgroundClassifiers based on molecular criteria such as gene expression signatures have been developed to distinguish Burkitt lymphoma and diffuse large B cell lymphoma, which help to explore the intermediate cases where traditional diagnosis is difficult. Transfer of these research classifiers into a clinical setting is challenging because there are competing classifiers in the literature based on different methodology and gene sets with no clear best choice; classifiers based on one expression measurement platform may not transfer effectively to another; and, classifiers developed using fresh frozen samples may not work effectively with the commonly used and more convenient formalin fixed paraffin-embedded samples used in routine diagnosis.MethodsHere we thoroughly compared two published high profile classifiers developed on data from different Affymetrix array platforms and fresh-frozen tissue, examining their transferability and concordance. Based on this analysis, a new Burkitt and diffuse large B cell lymphoma classifier (BDC) was developed and employed on Illumina DASL data from our own paraffin-embedded samples, allowing comparison with the diagnosis made in a central haematopathology laboratory and evaluation of clinical relevance.ResultsWe show that both previous classifiers can be recapitulated using very much smaller gene sets than originally employed, and that the classification result is closely dependent on the Burkitt lymphoma criteria applied in the training set. The BDC classification on our data exhibits high agreement (~95 %) with the original diagnosis. A simple outcome comparison in the patients presenting intermediate features on conventional criteria suggests that the cases classified as Burkitt lymphoma by BDC have worse response to standard diffuse large B cell lymphoma treatment than those classified as diffuse large B cell lymphoma.ConclusionsIn this study, we comprehensively investigate two previous Burkitt lymphoma molecular classifiers, and implement a new gene expression classifier, BDC, that works effectively on paraffin-embedded samples and provides useful information for treatment decisions. The classifier is available as a free software package under the GNU public licence within the R statistical software environment through the link http://www.bioinformatics.leeds.ac.uk/labpages/softwares/ or on github https://github.com/Sharlene/BDC.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-015-0187-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas

Sha¹,

Barrans²,

Care³

et al. 2015

Genome Med

View full text Add to dashboard Cite

show abstract

“…IgH amplification with or without MYC amplification, IgH-C-MYC translocation, and IgH-BCL2 translocations are reported in DLBCL-unclassified diseases. Among them, low-level IgH amplification had a higher survival with multiple relapses [4]. 14q 24-32 amplification accompanied with complex chromosomal/genetic alterations such as t(11; 14), monoallelic deletion of Tp53, and TP53 mutations are reported in mantle cell lymphoma leading to poor prognosis [5].…”

Section: Introductionmentioning

confidence: 99%

Case Report of a Rare Incidence of IgH Amplification Leading to Acute Kidney Injury in a Multiple Myeloma Patient

Thanikachalam

Srinivasalu

et al. 2021

Case Rep Oncol

View full text Add to dashboard Cite

We present a case report of a 62-year-old male, treated for kappa light chain multiple myeloma with chemotherapy followed by autologous stem cell transplant (ASCT) in 2014. He has been in complete remission for 4 years. In 2018, he was evaluated for hypercreatinemia and acute kidney injury(AKI) with a suspicion of disease relapse; he underwent evaluation with bone marrow aspiration cytology which showed no evidence of relapse. However, careful cytogenetic analyses showed IgH amplification (14q32) which probably was the cause for AKI in the absence of any structural abnormality in the kidney. Heavy chain deposition leads to AKI in multiple myeloma, and its association with IgH amplification leading to AKI is reported here. Though heavy chain deposition leading to AKI is common, IgH amplification at chromosome level is the first case observed.

show abstract

“…The B-UNC/BL/DLBCL type belongs to the heterogeneous category that does neither meet the criteria for classical BL nor for DLBCL, and it is usually characterized by complex karyotypes, aggressive behavior and a poor prognosis [1,2,3,4]. …”

Section: Figmentioning

confidence: 99%

Soft Tissue B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma Diagnosed by Fine Needle Aspiration Cytology

Perak

Pavlovic²,

Lozić³

et al. 2015

Acta Cytologica

View full text Add to dashboard Cite

IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt’s lymphoma

Cited by 3 publications

References 8 publications

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas

Case Report of a Rare Incidence of IgH Amplification Leading to Acute Kidney Injury in a Multiple Myeloma Patient

Soft Tissue B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma Diagnosed by Fine Needle Aspiration Cytology

Contact Info

Product

Resources

About